Niquitin Cq (Nicotine)

Nicotine, the active ingredient in Niquitin Cq, is a nicotinic receptor agonist presented as a transdermal patch for transdermal use. It treats nicotine dependence and aids smoking cessation in adults.

GNH USA supplies Niquitin Cq as a licensed, GDP‑compliant international pharmaceutical supplier serving pharmacies and clinics worldwide.

Niquitin Cq is a nicotine replacement product used within the smoking cessation pathway.

Smoking cessation: helps adult smokers reduce cravings and withdrawal symptoms to quit tobacco use. Tobacco use disorder: supports gradual reduction of nicotine intake during a quit attempt. Relapse prevention: assists individuals who have quit smoking to maintain abstinence.

Niquitin Cq may cause a range of skin‑related and systemic reactions.

Common Side Effects: - Skin irritation at the application site - Redness or erythema - Itching or pruritus - Burning sensation on the skin - Sleep disturbance or insomnia - Vivid dreams or abnormal sleep patterns

Serious or Rare Side Effects: - Allergic reaction (rash, swelling, hives) - Severe skin rash or dermatitis - Dizziness or light‑headedness - Hypotension (low blood pressure) - Nicotine poisoning (nausea, vomiting, rapid heartbeat) - Rare cardiovascular events (e.g., chest pain)

Before using Niquitin Cq, consider the following safety measures.

Assess cardiovascular status: avoid use in recent myocardial infarction or unstable angina. Do not combine with other nicotine products: risk of nicotine overdose. Monitor skin reactions: discontinue if severe irritation occurs. Avoid use in pregnancy or breastfeeding unless advised by a healthcare professional. Store at room temperature: keep in the original pouch, protect from moisture and direct heat.

Niquitin Cq can interact with several medication classes.

Major Interactions (Avoid): - Combined use with other nicotine replacement therapies (patches, gum, lozenges) - Monoamine oxidase inhibitors (MAOIs) – may enhance nicotine effects - Certain antipsychotics (e.g., clozapine) – increased plasma levels

Moderate Interactions (Monitor Closely): - CYP1A2 substrates (theophylline, clozapine) – nicotine may induce metabolism - Warfarin – possible alteration of anticoagulant effect - Insulin or oral hypoglycemics – nicotine may affect blood glucose control